Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
X Sun, Z Cui, Q Wang, L Liu, X Ding, J Wang, X Cai… - Autoimmunity …, 2024 - Elsevier
Background Formation of anti-drug antibodies (ADAs) against biologics is an important
cause of psoriasis treatment failure. Objective This study aimed to summarize the …
cause of psoriasis treatment failure. Objective This study aimed to summarize the …
Risk of candidiasis associated with interleukin-17 inhibitors: implications and management
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab,
brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These …
brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These …
Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice
J Zhou, Y Yuan, Y Liu, M Chu, H Liu… - Experimental …, 2024 - Wiley Online Library
A number of randomized controlled trials and real‐world studies have demonstrated the
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries
J Vyas, JR Johns, FM Ali, RK Singh… - British Journal of …, 2024 - academic.oup.com
Background Over 29 years of clinical application, the Dermatology Life Quality Index (DLQI)
has remained the most used patient-reported outcome (PRO) in dermatology due to its …
has remained the most used patient-reported outcome (PRO) in dermatology due to its …
Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a …
Q Beytout, S Afach, R Guelimi, E Sbidian… - Journal of Clinical …, 2024 - Elsevier
Objectives Incomplete reporting of safety outcomes in quality and availability of safety
reporting in published articles of randomized clinical trials (RCTs) were described in …
reporting in published articles of randomized clinical trials (RCTs) were described in …
Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab
LE Tomalin, F Kolbinger, M Suprun… - Clinical and …, 2024 - academic.oup.com
Background Secukinumab, an anti-interleukin (IL)-17A monoclonal antibody, induces
histological and molecular resolution of psoriatic plaques by 12 weeks. However, the long …
histological and molecular resolution of psoriatic plaques by 12 weeks. However, the long …
Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab
LE Tomalin, F Kolbinger, M Suprun… - Clinical and …, 2024 - academic.oup.com
Background Secukinumab, an anti-IL-17A monoclonal antibody, induces histological and
molecular resolution of psoriatic plaques by 12 weeks. However, the long-term effects of …
molecular resolution of psoriatic plaques by 12 weeks. However, the long-term effects of …
[HTML][HTML] Assessing the impact of immunosuppressive therapies on the risk of hypertension
HE Alosaimi - 2024 - theses.gla.ac.uk
Background Although it has a significant impact on morbidity and mortality, hypertension is a
major global health concern that is frequently neglected. Despite its prevalence, the role of …
major global health concern that is frequently neglected. Despite its prevalence, the role of …